← Eichor
Condition: Drug Resistant Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Drug Resistant

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Romiplostim for Oral TPO-RA Resistant ITP
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07612319VNS Algorithm for Advanced Dosing
NA · 1 location(s) · Fernando Vale · NCT07725601Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
NA · 1 location(s) · Indiana University · NCT07119658Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
NA · 1 location(s) · Royal Marsden NHS Foundation Trust · NCT07673861Network Effects of Therapeutic Deep Brain Stimulation
NA · 1 location(s) · The University of Texas Health Science Center, Houston · NCT05600738Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia
Phase N/A · 1 location(s) · University of Namibia · NCT05022238Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy
NA · 1 location(s) · Hospices Civils de Lyon · NCT06545214Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/Phase 2 · 1 location(s) · China Medical University Hospital · NCT06071013Fecal Microbiota Transplantation for the Prevention of Infectious Complications After Liver Transplantation
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06782880Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors,
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT07073755Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Phase 2/Phase 3 · 6 location(s) · University of California, San Francisco · NCT06441006A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist
Phase 3 · 329 location(s) · Merck Sharp & Dohme LLC · NCT06136650Comorbid Obesity and Depression With an Anti-inflammatory Medication
NA · 1 location(s) · King's College London · NCT06537921Effectiveness and Implementation of a National Guideline for Acute Respiratory Tract Infections to Reduce Antibiotic Pre
NA · 1 location(s) · Center for Primary Care and Public Health (Unisante), Univer · NCT07396428Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · Georgiamune Inc · NCT06425926Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance
Phase N/A · 1 location(s) · Beijing Friendship Hospital · NCT06779864Novel Triple-dose Tuberculosis Retreatment Regimen
Phase 3 · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT04260477A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy
NA · 1 location(s) · Cliniques universitaires Saint-Luc- Université Catholique de · NCT06304389Myeloma Novel Drug Discovery Ver 1.2
Phase N/A · 1 location(s) · Institute of Cancer Research, United Kingdom · NCT05968417Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resi
Phase 2 · 1 location(s) · National Institute of Mental Health (NIMH) · NCT06511908Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant
Phase 3 · 10 location(s) · Newron Pharmaceuticals SPA · NCT07184619Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
NA · 1 location(s) · University of California, San Francisco · NCT05553236Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics
Phase N/A · 2 location(s) · IRCCS San Raffaele · NCT05780099A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combinatio
Phase 1 · 5 location(s) · Regeneron Pharmaceuticals · NCT06469281Atlas of Human Cognition by SEEG (MAPCOG-SEEG)
Phase N/A · 4 location(s) · University Hospital, Grenoble · NCT03644732Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
NA · 1 location(s) · West Virginia School of Osteopathic Medicine · NCT06049420
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.